PeptideInfo
Back to Directory

Selank

Phase II Trials

Also known as: TP-7

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Selank is a synthetic heptapeptide analogue of the endogenous immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic and nootropic effects. It has been approved as a drug in Russia.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

  • Immune Support
  • Cognitive Enhancement
Mechanism of Action

Research suggests Selank may modulate the expression of BDNF and serotonin metabolic systems, influence GABA-A receptor function, and exhibit immunomodulatory effects through enkephalin-related pathways.

Safety Notes

Approved in Russia as a drug. Limited Western clinical trial data. Generally reported as well-tolerated in Russian studies.

Read More

Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.

Research Profile

Half-Life

~2 minutes (short; nasal administration studied for longer effect)

Administration

intranasal, subcutaneous injection

Legal Status (US)

Research chemical in the US. Not FDA-approved.

32 indexed research passages

Categories
Cognitive & NeurologicalImmune & Inflammation
Research Interest Areas
Immune SupportCognitive Enhancement